8 news items
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
as investigational MC4R agonists LB54640 and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm's
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
as investigational MC4R agonists LB54640 and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm's
Rhythm Pharmaceuticals Announces Publication Of Results From Phase 2 Study Of Setmelanotide For The Treatment Of Hypothalamic Obesity In The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
, Department of Pediatrics, University of Washington. "In this first study to investigate the use of setmelanotide as a targeted treatment
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
and Division of Endocrinology, Department of Pediatrics, University of Washington. "In this first study to investigate the use of setmelanotide as a targeted
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
RYTM
24 Apr 24
clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists LB54640 and RM-718, and a preclinical
uid 3gdhvrwojvmvg
RYTM
16 Apr 24
development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists LB54640 and RM-718, and a preclinical suite of small
erisy3 ox3x2097elx5zmbtjh0ng32z1yliva8tcef4c8pkmelqqxjtz5
RYTM
11 Mar 24
development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists LB54640 and RM-718, and a preclinical suite of small
p12rpve9cawck2vz3ouzz4dmaalk3zw4dk24n6d
RYTM
6 Mar 24
, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists LB54640
- Prev
- 1
- Next